Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23711623 | 1.00 | CYP51A1 (0.50) | CYP51A1PYGL | |
| SCHEMBL21702265 | 0.95 | CYP51A1 (0.49) | CYP51A1PYGL | |
| SCHEMBL21702303 | 0.92 | CTSL (0.46) | — | |
| SCHEMBL23712082 | 0.92 | CTSL (0.46) | — | |
| SCHEMBL23506529 | 0.92 | PYGL (0.53) | CYP51A1PYGL | |
| SCHEMBL21702185 | 0.92 | PYGL (0.53) | CYP51A1PYGL | |
| SCHEMBL26494064 | 0.91 | — | — | |
| SCHEMBL23506503 | 0.91 | CTSL (0.50) | — | |
| SCHEMBL21702077 | 0.91 | CTSL (0.50) | — | |
| SCHEMBL23506311 | 0.91 | PYGL (0.54) | PYGL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230133600-A1 | PHARMACEUTICAL USE OF KETOAMIDE-BASED COMPOUND | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2023-05-04 | — | — | US | disclosed |
| WO-2021151387-A1 | PHARMACEUTICAL USE OF KETOAMIDE-BASED COMPOUND | 中国科学院上海药物研究所 | 2021-08-05 | — | — | WO | disclosed |
| EP-3835296-A1 | KETOAMIDE COMPOUND AND PREPARATION METHOD, PHARMACEUTICAL COMPOSITION, AND USE THEREOF | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2021-06-16 | — | — | EP | disclosed |
| WO-2020030143-A1 | KETOAMIDE COMPOUND AND PREPARATION METHOD, PHARMACEUTICAL COMPOSITION, AND USE THEREOF | 中国科学院上海药物研究所 | 2020-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230133600-A1 | PHARMACEUTICAL USE OF KETOAMIDE-BASED COMPOUND | CTSL, CTSV, CTSS | CYP51A1 33/4885PYGL 1162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.